Company / Shareholders' Equity
Traws Pharma, Inc. Shareholders' Equity History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$31.6M
FY2024
5-year range
-$31.6M / $46.1M
FY2020-FY2024
Trend
-211.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Traws Pharma, Inc. reports negative total equity of -$32M in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$32M in FY2024.
Declined from $46M to -$32M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, shareholders' equity decreased 211.7% year-over-year.
- Peak shareholders' equity was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -42.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$31.6M | -211.7% |
| FY2023 | $28.3M | -38.6% |
| FY2022 | $46.1M | +646.9% |
| FY2021 | $6.2M | -46.6% |
| FY2020 | $11.6M | +114.9% |
| FY2019 | $5.4M | +0.0% |
| FY2018 | $5.4M | +146.1% |
| FY2017 | -$11.7M | -372.1% |
| FY2016 | $4.3M | -57.1% |
| FY2015 | $10.0M | -56.0% |
As of FY2024 · SEC 10-K Annual Filings · Last checked Jun 28, 2026